FDA Real-Time Trial Data and AI Plan: What Biotech Investors Should Watch
The FDA's latest move is not a promise to approve drugs faster by default. It is a sign that the agency wants to close the gap between what is happening inside a trial and when regulators can actually see it. That may sound subtle, but in biotech it matters a lot. Every month of delay affects capital, timelines, and the pace at which a company can move from one development phase to the next.